Hone Health Review 2026: Pricing, Labs, and Honest Take After 12 Months of Data

Last updated: May 20, 2026 · Medically reviewed by Dr. Marcus Tan, MD · ~9 min read

What Hone Health is (and isn’t) in 2026

Hone Health launched in 2020 and quickly became the best-capitalized direct-to-consumer hormone optimization brand in the U.S. After a Series A round and a publicly discussed (but not closed) SPAC conversation, Hone settled into operating as a private telehealth platform with a clear thesis: take the friction out of TRT for men whose primary care doctors won’t engage with the topic.

In 2026, Hone is a 50-state-licensed DTC clinic offering men’s hormone optimization, a women’s HRT track added in 2024, and a small but legitimate biomarker-tracking product for users who don’t qualify for or don’t want medication. It is not a peptide clinic, not a GLP-1 specialist, and not a concierge service. It is also not the cheapest option in the market — Henry Meds and PeterMD undercut on price — but the polish of the product and the depth of the lab partnerships are difficult to match at the DTC tier.

For a shorter brand snapshot and side-by-side scoring, see our original Hone Health brand review. This piece goes deeper on the 2026 pricing math, the women’s HRT expansion, and where Hone falls short.

[provider=”hone-health”]

Hone membership tiers explained — Basic, Plus, Premium

Hone restructured its membership in early 2025 into three tiers. As of May 2026:

• Basic — $25/mo: biomarker tracking only. Periodic at-home test kits, dashboard, no prescription. Useful for guys who want data without committing to TRT.
• Plus — $129/mo: hormone optimization with labs, limited prescription scope (typically clomiphene or enclomiphene, sometimes anastrozole). No testosterone cypionate at this tier.
• Premium — $149/mo: full TRT — testosterone cypionate, cream, troches, plus ancillaries (anastrozole, hCG, enclomiphene). Includes the standard consult schedule plus 90-day retests in year 1.

Premium is the tier you want if TRT is the goal. Plus is for men with secondary hypogonadism who are trying the enclomiphene/clomiphene route to preserve fertility before considering replacement.

2026 pricing breakdown: membership + medication + labs

Hone’s pricing is more transparent than most DTC competitors, but the all-in math still surprises new patients. Here’s the realistic 2026 build:

Realistic year-1 totals:

• Cypionate-only TRT: ~$1,900/yr
• Cypionate + anastrozole: ~$2,170/yr
• Cream-based TRT: ~$2,290/yr
• Enclomiphene-only (Plus tier): ~$2,050/yr

That puts Hone slightly below the mid-point of the DTC market — cheaper than Marek Health ($2,500–$4,000+) and Defy Medical ($2,400–$4,200), more expensive than Henry Meds ($1,068–$1,200/yr) and PeterMD.

Hone Health treatment options

Hone Premium supports four primary testosterone delivery methods, which is broader than most DTC competitors:

• Testosterone cypionate intramuscular or subcutaneous injection — the default. Most efficient, lowest cost, most durable serum levels.
• Testosterone cream — daily topical application. Useful for needle-averse men but more expensive and more variable absorption.
• Testosterone troches (oral lozenge) — niche delivery, useful for men who fail injection and topical.
• Enclomiphene — for men who want HPT-axis stimulation rather than exogenous replacement. Hone offers this but the brand built around this protocol is Maximus Tribe — see our original Maximus Tribe brand review for that mechanism.

The Hone intake flow: from $45 test kit to first dose

Hone’s intake takes about 14–21 days from sign-up to first injection. The flow:

1. Day 1: Sign up online, pay for the testing kit, complete the symptom questionnaire.
2. Days 3–7: Lab requisition arrives. You book a Quest or LabCorp draw — Hone covers both networks, so coverage is essentially universal in the U.S.
3. Days 7–14: Results land in the Hone dashboard. A second confirmatory testosterone draw is ordered if appropriate.
4. Days 14–18: Telehealth consult with a Hone-affiliated clinician.
5. Days 18–25: Prescription ships from Hone’s compounding pharmacy partner.

Re-testing happens at month 3 and month 6, then every 6–12 months — consistent with AUA 2024 monitoring guidance.

Lab work: Quest + LabCorp partnerships

Hone’s dual lab partnership is one of its strongest practical advantages. Quest Diagnostics and LabCorp together operate roughly 4,500+ patient service centers across the U.S. — virtually no ZIP code is uncovered. That matters because reputable TRT requires multiple in-person blood draws (baseline, month 3, month 6, then ongoing). A clinic limited to one lab network forces some patients to drive 45+ minutes; Hone almost never does.

The $78/year lab fee bundled into Premium membership covers all routine retests after the diagnostic phase. That’s unusually inclusive — at most DTC competitors, follow-up labs are billed à la carte and can add $150–$300/year.

[provider=”hone-health”]

Hone Health women’s HRT (launched 2024)

Hone added a women’s hormone replacement track in 2024. It treats perimenopausal and menopausal symptoms with estradiol, progesterone, and (in select cases) low-dose testosterone for women — the same off-label use that concierge clinics like Defy Medical have offered for years.

This is genuinely differentiated in the DTC TRT space: Maximus Tribe and Marek Health do not treat women; Henry Meds is GLP-1-centric; Defy Medical does treat women but at concierge pricing. If a household wants both partners on a single hormone platform, Hone is currently the only DTC option that delivers that under one membership family.

Trustpilot, BBB, and Reddit sentiment

As of May 2026, Hone’s Trustpilot score sits around 4.0/5 across several thousand reviews. The pattern of complaints is consistent:

• Positive: clean dashboard, fast shipping, predictable pricing, knowledgeable clinicians.
• Negative: billing disputes after cancellation (a common DTC pattern), slower-than-expected response on dose-adjustment messages, occasional shipping delays from the compounding pharmacy partner.

Reddit’s r/Testosterone and r/TRT subreddits run roughly net-positive on Hone, with most criticism centered on the membership-plus-medication pricing structure (some users would prefer to pay only for medication) rather than clinical quality.

Where Hone falls short (and where concierge wins)

Hone is the right fit for the median TRT patient. It is not the right fit for these cases:

• You want peptides. Hone does not prescribe BPC-157, ipamorelin, sermorelin, or other peptides. Marek Health and Defy Medical do.
• You want aggressive optimization. Hone targets clinical replacement (mid-to-upper reference range). Optimization-focused clinics target supraphysiologic levels under tighter monitoring — that’s Marek’s lane.
• You have complex endocrine history. Defy Medical’s physician-led model handles secondary hypogonadism with multi-modal protocols (hCG + cypionate + anastrozole + thyroid) more flexibly than Hone’s templated approach.
• You want fertility preservation as a first-line strategy. Maximus Tribe defaults to enclomiphene; Hone offers it as a secondary option.

Hone vs Maximus vs Defy: quick stack-up

Who should and shouldn’t use Hone Health

Hone is the right choice if: you want a clean, predictable DTC TRT experience; you live anywhere in the 50 states; you prefer cypionate injections; you want a single platform that can also treat a partner; you value design polish.

Hone is the wrong choice if: you want peptides or GLP-1 stacking; you want concierge-level dose personalization; you want fertility preservation as the default protocol; you’re price-shopping under $1,500/yr.

Frequently asked questions

Related reading on BestMedsHub

• Testosterone telehealth hub
• Our original Hone Health brand review
• Hone vs Maximus 2026 — replacement vs stimulation
• Best online TRT clinics for 2026
• TRT cost in 2026
• TRT side effects and monitoring
• Online testosterone prescription 2026 — legality explainer

Sources

• Hone Health pricing and membership pages, verified May 2026.
• Hone Health Trustpilot profile, accessed May 2026.
• American Urological Association. Testosterone Deficiency Guideline — 2024 Amendment.
• Bhasin S. et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2018 (current).
• U.S. FDA. Testosterone cypionate prescribing information (current revision).
• Lincoff AM et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). NEJM, 2023.
• U.S. DEA. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities, December 19, 2025.